Medical device company SynerFuse has tapped neurosurgeon Michael Park, MD, PhD, as its chief technology officer.
The SynerFuse e-TLIF procedure, an ultralow-energy therapy, is used to address chronic low back and leg pain for spinal fusion patients.
Dr. Park is a former principal investigator for the SynerFuse proof-of-concept study, and a primary inventor of the technology, according to a June 10 news release shared with Becker’s.
“SynerFuse technology is revolutionizing the way spinal disease is treated by offering a simultaneously anatomical and neurological solution and therapy to patients suffering from chronic low back and leg pain,” Dr. Park said in the release.
Dr. Park is a board-certified neurosurgeon, an associate professor, MnDRIVE neuromodulation scholar, and director of stereotactic and functional neurosurgery in the department of neurosurgery and neurology at the University of Minnesota in Minneapolis.
He specializes in neuromodulation, a surgical therapy that modulates brain activity to treat Parkinson’s disease, essential tremor and dystonia. He also uses spinal cord stimulation and intrathecal drug delivery to treat cancer pain and chronic pain.
